SCYNEXIS Inc. announced that it has entered into a binding memorandum of understanding with GlaxoSmithKline Intellectual Property (No. 3) Limited $(GSK)$ to amend their exclusive license agreement related to ibrexafungerp, including the approved product BREXAFEMME®. Under the amended terms, SCYNEXIS has agreed to wind down and terminate the Phase 3 MARIO study of ibrexafungerp for the treatment of invasive candidiasis. As part of the agreement, SCYNEXIS will receive a $22 million payment from GSK, as well as an additional $2.3 million payment related to the wind-down and termination activities. SCYNEXIS will not receive further milestone payments from GSK specifically associated with the MARIO study.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCYNEXIS Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178253-25-000006), on October 15, 2025, and is solely responsible for the information contained therein.